黄芪甲苷对心血管保护功能的研究进展  

Cardiovascular protective effects of astragaloside Ⅳ

作　　者：承燕[1] 江时森[1] 

机构地区：[1]南京大学医学院临床学院(南京军区南京总医院)心脏内科,南京医学博士研究生210002

出　　处：《医学研究生学报》2011年第6期637-640,共4页Journal of Medical Postgraduates

基　　金：南京军区"十一五"重点课题基金(06Z38)

摘　　要：在中国传统医学中,尤其在治疗心血管疾病方面,黄芪被广泛使用了千年。作为黄芪的主要有效成分,黄芪甲苷(AstragalosideⅣ,ASTⅣ)不仅能增强超氧化物歧化酶(superoxide dismutace,SOD)等自由基清道夫的活力,而且本身具有清除自由基的能力。它还能通过升高内皮型一氧化氮合成酶(endothelial nitric oxide synthase,eNOS)水平,减轻细胞内钙超载,抑制蛋白激酶C(protein kinase C,PKC)的过度表达和改良细胞骨架重构来改善心血管功能。ASTⅣ在防治动脉粥样硬化上也有相当的潜力,其机制可能为下调肿瘤坏死因子α(tumor mecrosis factor-α,TNF-α)、提高过氧化物酶增殖活化受体γ(peroxisome proliferator-activated receptorsγ,PPAR-γ)的表达等。另外,ASTⅣ还能升高病毒性心肌炎小鼠的干扰素γ(interferon gamma,IFN-γ)水平,这提示了其在免疫系统的作用。ASTⅣ是一种值得进一步研究的备选新药。Astragalus membranaceus(AM) has been widely used in traditional Chinese medicine for centuries,especially for cardiovascular diseases.Astragaloside Ⅳ(ATS Ⅳ),one of the main active ingredients in AM,not only promotes the activity of free radicals,but also has the ability to clear them away.It improves the cardiovascular function by increasing the eNOS level,reducing intracellular Ca2+ overload,inhibiting PKC overexpression and ameliorating cytoskeleton remodeling.It has also exhibited its effect on atherosclerosis by down-regulating TNF-α and up-regulating PPAR-γ.Moreover,it can increase the IFN-γ level in rats with myocarditis,indicating its immune effect.In a word,ATS Ⅳ is worth to be further studied as a drug candidate.

关 键 词：黄芪甲苷 心血管 自由基 钙超载 

分 类 号：R[医药卫生]